TABLE 3.
Preferred but not perceived discussion of short‐ and long‐term treatment consequences (SDM step 2)
| Breast cancer | Haematological cancer | Colon cancer | Prostate cancer | Other cancer types | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Total | N = 886 | N = 579 | N = 563 | N = 400 | N = 826 | |||||
| Short‐term | Long‐term | Short‐term | Long‐term | Short‐term | Long‐term | Short‐term | Long‐term | Short‐term | Long‐term | |
| Preferred but not perceived discussion consequences a | 26.7 (273) | 36.2 (321) | 20.4 (118) | 25.6 (148) | 17.4 (98) | 17.6 (99) | 13.3 (53) | 17.0 (68) | 22.5 (186) | 23.8 (197) |
| Fatigue a | 10.3 (91) | 16.4 (145) | 5.5 (32) | 10.2 (59) | 4.6 (26) | 7.1 (40) | 3.3 (13) | 4,0 (16) | 7.0 (58) | 9.6 (79) |
| Diminished physical capacity a | 10.2 (90) | 13.3 (118) | 4.3 (25) | 7.4 (43) | 5.3 (30) | 5.0 (28) | 3,0 (12) | 4.3 (17) | 7.0 (58) | 7.6 (63) |
| Sexual dysfunction a | NA | 9.8 (87) | NA | 4.5 (26) | NA | 6.9 (39) | NA | 6.5 (26) | NA | 5.2 (43) |
| Gastrointestinal complaints a | 3.3 (29) | 3.0 (27) | 4.1 (24) | 3.3 (19) | 3.7 (21) | 2.3 (13) | 2.5 (10) | 2.8 (11) | 3.8 (31) | 3.6 (30) |
| Osteoporosis a | NA | 7.8 (69) | NA | 2.9 (17) | NA | 1.8 (10) | NA | 2.5 (10) | NA | 2.8 (23) |
| Weight shift/problems eating or drinking a | 5.8 (51) | 6.7 (59) | 2.8 (16) | 2.1 (12) | 3.2 (18) | 2.3 (13) | 1.0 (4) | 1.0 (4) | 3.0 (25) | 3.5 (29) |
| Pain a | 6.5 (58) | 10.2 (90) | 2.6 (15) | 2.9 (17) | 2.3 (13) | 1.8 (10) | 2.0 (8) | 1.5 (6) | 4.0 (33) | 4.1 (34) |
| Neuropathy a | 8.1 (72) | 11.5 (102) | 5.2 (30) | 7.4 (43) | 2.1 (12) | 3.7 (21) | 0.3 (1) | 0.8 (3) | 3.3 (27) | 3.9 (32) |
| Cardiological problems a | NA | 7.1 (63) | NA | 4.1 (24) | NA | 0.9 (5) | NA | 0.8 (3) | NA | 1.7 (14) |
| Hormonal dysfunction a | 6.5 (58) | 10.2 (90) | 1.9 (11) | 1.2 (7) | 0.9 (5) | 1.2 (7) | 2.5 (10) | 2.0 (8) | 1.5 (12) | 2.1 (17) |
| Oral/dental problems a | 8.0 (71) | 9.0 (80) | 2.6 (15) | 3.6 (21) | 1.2 (7) | 0.9 (5) | 1.3 (5) | 1.3 (5) | 2.1 (17) | 3.0 (25) |
| Concentration problems a | 9.1 (81) | 15.3 (136) | 5.5 (32) | 8.5 (49) | 3.0 (17) | 3.2 (18) | 1.0 (4) | 1.3 (5) | 5.2 (43) | 6.9 (57) |
| Lymphedema a | 6.8 (60) | 9.1 (81) | 0.7 (4) | 0.3 (2) | 0.5 (3) | 0.5 (3) | 1.5 (6) | 1.5 (6) | 1.5 (18) | 3.9 (32) |
| Memory problems a | 8.8 (78) | 14.2 (126) | 4.8 (28) | 7.8 (45) | 2.7 (15) | 2.3 (13) | 1.0 (4) | 1.5 (6) | 4.4 (36) | 6.1 (50) |
| Depressive symptoms a | 8.8 (78) | 9.1 (81) | 3.3 (19) | 4.7 (27) | 2.5 (14) | 2.3 (13) | 2.3 (9) | 4.0 (16) | 5.8 (48) | 6.1 (50) |
| Secondary tumours a | NA | 3.2 (28) | NA | 2.8 (16) | NA | 1.1 (6) | NA | 1.3 (5) | NA | 1.7 (14) |
| Stress a | 5.3 (47) | 4.6 (41) | 2.6 (15) | 2.9 (17) | 1.1 (6) | 2.1 (12) | 1.5 (6) | 0.8 (3) | 2.8 (23) | 4.2 (35) |
| Anxiety a | 5.3 (47) | 6.8 (60) | 3.5 (20) | 2.6 (15) | 3.2 (18) | 2.3 (13) | 1.0(4) | 2.3(9) | 4.7 (39) | 5.1 (42) |
| Dyspnoea/shortness of breath a | 4.7 (42) | NA | 1.7 (10) | NA | 0.7 (4) | NA | 0.5 (2) | NA | 1.7 (14) | NA |
Note: The following treatment consequences were reported by less than 2% of the study population and are not presented in this table: nausea, hair loss, incontinence, and fertility problems. Higher means or medians indicate higher levels of preferred but not perceived discussion.
Abbreviations: NA, not applicable; SDM, shared decision making.
a
Results presented as % (N).